Drug Profile
ATP7B gene therapy - DeveloGen
Latest Information Update: 25 Jul 2001
Price :
$50
*
At a glance
- Originator DeveloGen
- Class Gene therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatolenticular degeneration
Most Recent Events
- 25 Jul 2001 Discontinued-Preclinical for Wilson's disease in Germany (Unknown route)
- 27 Nov 2000 HepaVec has been acquired by DeveloGen
- 07 Dec 1999 New profile